Company Overview
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Why Investors Should Care
Trades at a P/E of 0.1, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.07.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $856.00K (-34.5% YoY); net profit $-12.18M.
- Trailing 12 Months Year-on-year growth — revenue -34.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -14.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -14.03% |
| 1 Year: | -34.50% |
Stock Price Performance
| 1 Year: | -88.98% |
| 6 Months: | -9.09% |
| 3 Months: | -51.06% |
| 1 Month: | -26.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)35.84 · Neutral
P/E of 0.05 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -14.0% CAGR over 5 years.
- Trading 90.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPRC SciSparc Ltd. PHARMA | 5.10 | 0.05 | $117.67M | 0.00% | - | - | -14.03% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.35M | 2.88M | 1.31M | 856.00K |
| Cost of Revenue | - | 322.00K | 683.00K | 800.00K | 225.00K |
| Gross Profit | - | 1.02M | 2.20M | 506.00K | 631.00K |
| Operating Expenses | - | 9.31M | 7.97M | 7.75M | 9.38M |
| Operating Income | - | -8.29M | -5.77M | -7.24M | -8.75M |
| EBITDA | - | -2.35M | -5.31M | -6.97M | -12.32M |
| Interest Expense | - | 36.00K | 9.00K | 30.00K | 11.00K |
| Pretax Income | - | -2.58M | -5.86M | -7.49M | -12.56M |
| Tax Provision | - | 14.00K | 22.00K | -14.00K | 0 |
| Net Income | - | -2.59M | -5.12M | -6.28M | -12.18M |
| Diluted EPS | -9,203.50 | -1,874.19 | 2,374.55 | 203.89 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 10.61M | 11.18M | 10.35M | 7.62M |
| Current Assets | - | 4.51M | 6.45M | 7.50M | 5.44M |
| Cash & Equivalents | - | 3.57M | 2.08M | 1.54M | 4.59M |
| Inventory | - | 668.00K | 742.00K | 113.00K | 75.00K |
| Receivables | - | 77.00K | 22.00K | 10.00K | 10.00K |
| Total Liabilities | - | 4.16M | 1.59M | 1.41M | 2.48M |
| Current Liabilities | - | 4.16M | 1.57M | 1.40M | 2.25M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 27.00K | 76.00K | 46.00K | 366.00K |
| Total Equity | - | 6.45M | 7.61M | 8.15M | 4.24M |
| Shares Outstanding | - | 1.38K | 3.74K | 57.29K | 365.44K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -7.92M | -5.89M | -5.10M | -4.14M |
| Investing Cash Flow | - | -7.08M | -4.09M | -1.62M | -1.40M |
| Financing Cash Flow | - | 11.70M | 8.48M | 6.19M | 8.59M |
| Capital Expenditure | -35.00K | -4.87M | - | - | - |
| Free Cash Flow | - | -12.79M | -5.89M | -5.10M | -4.14M |
| Net Change in Cash | - | -3.30M | -1.50M | -536.00K | 3.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 76.1% | 76.3% | 38.7% | 73.7% |
| Operating Margin % | - | -615.2% | -200.5% | -554.5% | -1,022.1% |
| Net Margin % | - | -192.4% | -177.9% | -481.2% | -1,422.8% |
| ROE % | - | -40.2% | -67.3% | -77.1% | -287.3% |
| ROCE % | - | -128.5% | -60.1% | -80.9% | -163.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 3.75% | 21.23K | $95.77K |
| 2 | Jane Street Group, LLC | 2.92% | 16.50K | $74.40K |
| 3 | Citadel Advisors Llc | 1.96% | 11.06K | $49.90K |
| 4 | UBS Group AG | 0.80% | 4.52K | $20.38K |
| 5 | JPMORGAN CHASE & CO | 0.04% | 211 | $951 |
| 6 | Morgan Stanley | 0.04% | 200 | $902 |
| 7 | Royal Bank of Canada | 0.01% | 32 | $144 |
| 8 | SBI Securities Co., Ltd. | - | 12 | $54 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPRC
Why (SPRC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNUlpjTEplbFNfak00TmhWRU9EMkFJYTVfRVdYQ0o5UG1WT1JVTndMVzZGd2JyRDVFM3lNODE4eGplbFp0S0tnc2RUWWdrdXlCLUQteUdxSS11U1B2ZFdkZlpPWUpJdXBxZFhUdTM2eXo3VlVfdkd3SFNvam9PZUo5WDhfeEpLajNDVFVEaU…
A Tourette drug candidate achieved an average 21% tic reduction in an earlier study - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOcFZTWWxBQzhuYUtkb1Q0UmpJcC1JUDBTTzZEVTVxeVJXOFByX205cVh5dlVIYnQzUE9ZdTBaQWlMOHFNcWM1ekQ3VE5FTlhqNkl3WnUzc19KdzZodzd1RkxqWTdpaURQUF96dmdiS090bnJ0MXpPc0ZQVDI2ZXoyS3NidGVfa2piaV85dE…
$SPRC stock is up 29% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQYU5YSnVJMEtYRmh5OGlNY0VnQmtIWXlHWk9XMXBOQy1XSmN4Qm5pU1E2UlJqcGk4dGVRQUMtZVd2blNVRFkwWFJyUE5ZVmswTFZLcVlVelhEaHhIbi1zaDI1QXpEQVQ1Vm53OWxNMnpmZXFUY3MtS1ptQkJLVUJESUJwaVNxZ0phLWhTbn…
SPRC - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5TcjFxSHQzTFVpMDlmNEtwZHRTTnhxOFhneUxzQTJMWkJRUlJ3XzZhazQycDhIcnU3QjNPNG81SFBCY2stSGc?oc=5" target="_blank">SPRC</a> <font color="#6f6f6f">Finviz</font>…
SciSparc Ltd. SEC Filing (Sep 1, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNNTJsZERnenZkUW5yNHlGV0xQU0luTThJZzVsTDdKTXRJMFl1MHVGWGlKT2VaUklJeXo3djd3RzVkRnZoQldGSVpEY0p2enRKV2E2bGNfN3R6TS1xQ181Y0lEZ1owN05aWWFaZGxSLWVIcmxJVExPb0Y2RlI5Q0FoMTJZbUhiSzZ5TE94MT…
$SPRC stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQamZpRUZXVXBuc2JkSmtwY29yekI3eUZwLTBZVXhzQVFHZG52LS1xM05HQy12X1A0clE4YUFDYTRndmJVVG5aYXpvOXhKS0RWdUNtaUlkaktramRDM0x2aklqSEZ6eU1NRXh5ZWVoTUQzR1VJbjQwRkZ2cXR2WlZYd054VDRqelJONDEwWk…
SPRC — Frequently Asked Questions
What is the current share price of SciSparc Ltd. (SPRC)?
As of 2026-09-19 21:16 PDT, SciSparc Ltd. (SPRC) trades at $5.10 on NasdaqCM. Its 52-week range is $3.06 to $54.81.
What is the market capitalisation of SPRC?
SciSparc Ltd. (SPRC) has a market capitalisation of $117.67M on NasdaqCM.
What is the P/E ratio of SPRC?
SPRC trades at a trailing price-to-earnings (P/E) ratio of 0.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.39.
Is SPRC a good stock to buy?
This page provides a data-driven analysis of SciSparc Ltd. (SPRC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.